Question · asked by 1 review
Avalglucosidase alfa vs alglucosidase alfa: Treatment‐related AEs: total treatment‐emergent adverse events potentially related to treatment
- Population
- adults with LOPD
- Intervention
- Avalglucosidase alfa
- Comparison
- alglucosidase alfa
- Outcome
- Treatment‐related AEs: total treatment‐emergent adverse events potentially related to treatment
Avalglucosidase alfa showed no clear difference in treatment‐related AEs: total treatment‐emergent adverse events… compared with alglucosidase alfa (low certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Avalglucosidase alfa vs alglucosidase alfa Treatment‐related AEs: total treatment‐emergent adverse events potentially related to treatment · adults with LOPD Avalglucosidase alfa showed no clear difference in treatment‐related AEs: total treatment‐emergent adverse events… compared with alglucosidase alfa (low certainty). Enzyme replacement therapy for late‐onset Pompe disease (2023) · Cochrane Headline outcomes only | RR 0.92 [0.61, 1.4] | 1 study · 100 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.